

A STUDY OF NEW JERSEY SENATE BILL 1796

EXPANDS REQUIREMENTS FOR HEALTH
INSURANCE CARRIERS CONCERNING
PROSTATE CANCER SCREENING AND
REQUIRES COVERAGE BE PROVIDED WITHOUT
COST SHARING

Report to the New Jersey Senate

February 11, 2026

Mandated Health Benefits Advisory Commission



Table of Contents

Introduction.....1

Medical Evidence.....2

Social Impact4

Other States5

Discussion9

Financial Impact.....10

Conclusion13

Endnotes.....15

Appendix I Senate Bill No. 1796

Appendix II Review Request for Senate Bill No. 1796

INTRODUCTION

The Mandated Health Benefits Advisory Commission (MHBAC) has been asked to review S1796 (see Appendix I for a copy of the legislation), a bill that expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing. Specifically, the bill would require carriers “to provide coverage for an annual prostate cancer screening without cost sharing for men...between 40 and 75 years of age.” The bill would apply to health insurers, including health service corporations, hospital service corporations, medical service corporations, health maintenance organizations, group health insurers, health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs, and the State Health Benefits Program (SHBP) and School Employees' Health Benefits Program (SEHBP).

The coverage mandate that would be established under S1796 would expand existing prostate cancer screening coverage requirements that apply to certain carriers and certain markets and would establish a new coverage requirement for certain other carriers and other markets. Specifically, current law, P.L.1996, c.125, requires health, hospital, and medical service corporations, health maintenance organizations, and commercial group health insurers to cover prostate cancer screenings for men aged 50 and over who are asymptomatic and for men aged 40 and over with a family history of prostate cancer or other risk factors for prostate cancer. The current law only applies to the large group market; it does not apply to the individual or small employer markets. A separate law, P.L.2007, c.103, requires the State Employee Health Benefits Program and the School Employees' Health Benefits Program to cover routine adult physicals, including prostate examinations, but does not specify any terms and conditions for those examinations. Additionally, prostate cancer screenings are currently referenced as an example of a covered preventive service in the standard policy forms used by the Individual Health Coverage Program and the Small Employer Health Benefits Program.

Under S1796, the prostate cancer screening coverage requirement would additionally apply to commercial individual health insurers, health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs, the State Health Benefits Program, and the School Employees' Health Benefits Program. Although these markets may already cover prostate cancer screenings as a preventive care service outside of the existing state statutory mandate, S1796 could potentially expand the scope of that coverage to include additional services or require coverage for a broader population. Existing statutory coverage requirements do not exempt prostate cancer screenings from cost sharing requirements; under S1796, no deductible, coinsurance, copayment, or any other cost-sharing requirement on benefits would apply to covered prostate cancer screenings.

Under S1796, the prostate cancer screening requirement would apply to all men between 40 and 75 years of age and would not establish distinctions based on whether the covered individual has risk factors for prostate cancer. S1796 would also expand the definition of “prostate cancer

screening.” Under current law, covered screenings include a “medically recognized diagnostic examination including, but not limited to, a digital rectal examination and a prostate-specific antigen test (PSA).” Under the bill, covered screenings would additionally include associated laboratory work and subsequent follow up testing as directed by a physician, including, but not limited to urinary analysis, serum biomarkers, and medical imaging, including, but not limited to, magnetic resonance imaging. In defining “prostate cancer screening,” S1796 would also replace the current term “medically recognized diagnostic examination” with “medically viable methods for the detections and diagnosis of prostate cancer.”

The Mandated Health Benefits Advisory Commission Act (N.J.S.A. 17B:27D-1 *et seq.*) tasks the Commission with providing an independent analysis of the social, medical, and financial impact of proposed legislation referred to it for review. The Act does not ask the Commission to recommend whether to enact the legislation, and the Commission does not do so here. The MHBAC prepared this report using its own resources, including staff from the New Jersey Department of Banking and Insurance. Commission members contributed their professional expertise, on a voluntary basis, in helping to shape the presentation of this report, analyzing published research, and drafting and editing its various sections. The MHBAC has sought to include information from a number of reputable sources that it found credible but recognizes that opinions and analyses may differ.

MEDICAL EVIDENCE

Prostate cancer is a type of cancer that occurs in the prostate, which is a small gland that is part of the male reproductive system. In broad terms, prostate cancer only occurs in men, tends to develop later in life, is frequently detected early, and generally grows slowly. Prostate cancer is one of the more treatable forms of cancer, although more serious complications can develop, particularly if the cancer goes undetected or spreads to other parts of the body. The causes of prostate cancer are not known, although certain factors, such as a family history of prostate or other cancers, have been associated with an increased risk of developing prostate cancer.ⁱ

According to the Mayo Clinic, early-stage prostate cancer may not initially present with symptoms, but when it does, symptoms can include blood in the urine, blood in the semen, and needing to urinate more often, especially at night.ⁱⁱ According to the Memorial Sloan Kettering Cancer Center, other symptoms can include trouble starting or stopping the flow of urine, trouble achieving an erection, painful ejaculation, and pain or stiffness in the hips, lower back, or upper thighs.ⁱⁱⁱ

The goal of prostate cancer screening is to identify any growth of malignant cells in the prostate early, before the cancer spreads into other parts of the body.^{iv} The most common prostate cancer screening tests include a prostate-specific antigen blood test (PSA) and a digital rectal exam (DRE), both of which may be performed individually or in combination with one another.^v The PSA test examines for a buildup of a protein made by the prostate gland in the bloodstream,

indicating possible prostate cancer. However, an elevated PSA level is not always indicative of prostate cancer.^{vi} For the DRE exam, a medical professional inserts a gloved, lubricated finger inside the rectum to feel the prostate for nodules or abnormal texture, shape, or size of the gland.^{vii} Some other diagnostic exams include a prostate MRI, ultrasound, biopsy, and cancer biomarkers tests.^{viii}

Treatments for prostate cancer include surgery, radiation, and medication.^{ix} Hormone therapy, chemotherapy, targeted therapy, and immunotherapy are among the other methods used to treat prostate cancer.^x In some cases, treatment may include the use of ablation therapy, which is the use of extreme cold, heat, or lasers to create scar tissue at the cancer site.^{xi} Active surveillance is a common treatment option for prostate cancer, particularly when the disease is detected in its early stages.^{xii} Using data from the SEER (Surveillance, Epidemiology, and End Results) database, which includes men diagnosed with prostate cancer between 2014 and 2020, the American Cancer Society (ACS) notes the 5-year relative survival rate—which compares people with the same type and stage of cancer to the general population—varies significantly based on the stage at diagnosis.^{xiii} The specific findings are as follows:

- **Localized stage** (cancer confined to the prostate): The 5-year relative survival rate is greater than 99%.
- **Regional stage** (cancer has spread to nearby structures or lymph nodes): The survival rate remains greater than 99%.
- **Distant stage** (cancer has spread to other parts of the body): The survival rate drops significantly to 37%.^{xiv}

When prostate cancer is detected at the localized stage, men often pursue a wider range of treatment options, including less invasive treatments such as active surveillance, focal therapy, or minimally invasive surgery.^{xv} In addition to enabling intervention when the disease is most treatable, early detection is also associated with faster recovery times, maintaining urinary and sexual function, and reducing the emotional burden that can accompany a later-stage diagnosis.^{xvi}

The causes of prostate cancer are not clear, but studies suggest the risk factors for prostate cancer may include older age, race and ethnicity, a family history of prostate cancer, a family history of DNA change, obesity, and smoking tobacco.^{xvii} Specifically, African American men have a greater risk of prostate cancer compared to all other races and ethnicities, and prostate cancers occurring in African American men tend to grow more quickly or be more advanced when detected.^{xviii}

The ACS recommends that men begin discussing prostate cancer screening with their healthcare provider based on their individual risk levels.^{xix} The ACS advises that men at average risk, who are expected to live at least 10 more years, should talk with their healthcare provider about the potential benefits and risks of screening starting at age 50.^{xx} Men at higher risk — including African American men and those with a first-degree relative (such as a father or brother) who was

diagnosed with prostate cancer before age 65 — should begin these discussions at age 45.^{xxi} The ACS recommends that men with the highest risk of developing prostate cancer, meaning men with more than one first-degree relative diagnosed with prostate cancer before age 65, should start conversations about prostate cancer screening at age 40.^{xxii} The ACS recommends that, for men who want prostate cancer screening, the primary method of screening should be a PSA test, which may be paired with a DRE screening.^{xxiii} It should be noted that the ACS, through its New Jersey chapter, is an advocacy group that has been lobbying in support of S1796.

In contrast, the United States Preventive Services Task Force (USPSTF) recommends that only men aged 55 to 69 be counseled about prostate cancer screening using the PSA test; the USPSTF has assigned this recommendation a Grade C.^{xxiv} For men aged 70 and older, the USPSTF gives the PSA screening a Grade D recommendation, meaning it advises against PSA-based screening in this age group.^{xxv} These grades follow an A-to-D scale, where an A indicates that the USPSTF strongly recommends the service due to a substantial net benefit, while a D signifies that the USPSTF advises against the service because it offers no net benefit or its harms outweigh the benefits.^{xxvi} Additionally, the USPSTF can give a service an “I statement” signifying current evidence for a service is insufficient and a balance between the benefits and harms cannot be determined.^{xxvii}

SOCIAL IMPACT

There are benefits and drawbacks to prostate cancer screening, and it is recommended that men have a detailed discussion with their healthcare providers and make a choice that best suits their preferences and values.^{xxviii} Prostate cancer screening is beneficial to the extent that it aids in detecting prostate cancer early, when the disease is easier to treat, leading to a better prognosis.^{xxix} Additionally, screening can provide individuals with more detailed information about their risk of prostate cancer. For example, if men know their baseline PSA levels, this can help them plan for future tests to monitor their prostate health.^{xxx}

In contrast, prostate cancer screenings can have limitations, as the benefits of testing may not outweigh the risks in all cases. For example, PSA testing can result in both false positives and false negatives – some patients will show elevated PSA levels even when cancer is not present, while tests of some patients who have prostate cancer will find normal PSA levels.^{xxxi} It is important for medical providers to be aware of these limitations and be ready to rule out any other possible reasons for elevated PSA levels or conduct additional screenings even in the absence of elevated PSA levels.^{xxxii} Some other barriers to prostate cancer screenings that men face include financial costs, time constraints (*e.g.*, work schedule), lack of awareness, and fear and anxiety.^{xxxiii} These particular barriers disproportionately affect minority groups and those of low socioeconomic status.^{xxxiv}

African American men are 70% more likely than white men to develop prostate cancer and twice as likely to die from it.^{xxxv} This racial health disparity is thought to be influenced by a complex interplay of social and environmental factors, such as access to healthcare, nutrition, and exposure to environmental pollutants.^{xxxvi} These differences, especially access to healthcare, lead to disparities in the stage at which cancer is diagnosed and the subsequent care African American men receive.^{xxxvii} The Memorial Sloan Kettering Cancer Center asserts that previous screening guidelines were based on studies that do not include a sufficient representation of African American men, which may have resulted in an underestimation of the benefits of prostate cancer screening for this demographic.^{xxxviii} To address the elevated risk, the Prostate Cancer Foundation (PCF) recommends that African American men should consider baseline PSA testing starting between the ages of 40 and 45.^{xxxix}

More generally, studies have shown some men who undergo prostate cancer screening experience adverse psychological effects. In a qualitative study, 397 men responded to a survey, split by a control group and a biopsy group. The control group (n=230) consisted of men who received normal screening results, and the biopsy group (n=167) consisted of men who had suspicious initial test screening results and then received a benign biopsy result.^{xl} Even after benign results, men in the biopsy group reported “substantial thinking and worrying about prostate cancer.”^{xli} 36% of men in the benign group also reported feeling that they were at an increased risk of prostate cancer, even though this was not accurate.^{xlii} In addition to the psychological impact, some men in the biopsy group reported “moderate-to-severe” pain from the biopsy.^{xliii} The authors of this study concluded that the potential physiological impact is an “underrecognized human cost of screening” and should be considered when discussing the benefits and drawbacks.^{xliv}

A study using the SEER Program database, which examined the cost of care from 2012 to 2016 among Medicare beneficiaries with a cancer diagnosis — including prostate cancer — found that, for all cancer types, beneficiaries diagnosed at more advanced stages incurred up to seven times higher costs than those diagnosed at earlier stages.^{xlv} Specifically, for prostate cancer, the total cost of care in year 1 was \$7,640 when diagnosed at stage I, compared to \$58,783 when diagnosed at stage IV.^{xlvi} The study found that, for all cancer types, although the total cost of care was lower in subsequent years when compared with year 1, disparities in the total cost of care associated with earlier-stage diagnoses as compared with later-stage diagnoses persisted in years 2–5.^{xlvii} The study's authors concluded that, for all cancers, earlier diagnosis may lead to “more efficient treatment and reduced management costs.”^{xlviii}

OTHER STATES

Nine states and Washington, DC have enacted legislation that, like S1796, requires commercial insurance coverage for prostate cancer screening and prohibits the application of cost-sharing.^{xlix} Table 1 provides an overview of the provisions of those state laws. Although there are additional

states with statutory coverage mandates for prostate cancer screenings in the commercial insurance market, in the interest of focusing the discussion on laws comparable to the provisions of S1796, this report will limit its analysis to those states that, like S1796, restrict the application of cost-sharing. The information in Table 1 is grouped by states with similar age and cancer risk requirements for coverage, with blocks of states separated by bolded lines.

Table 1. States with Prostate Screening Coverage Laws that Preclude Application of Cost-Sharing

State (Year)*	Tests and Procedures Covered	Scope of Coverage, including Age- and Risk-Based Requirements
Maryland (2020)	Preventive care screening services for prostate cancer, including a digital rectal examination and a PSA test	Men 40 to 75 years of age
Rhode Island (2021)	Preventive screening examinations and laboratory tests for prostate cancer from an in-network provider	Asymptomatic men
Oregon (2024)	PSA Screening	All men regardless of risk
Washington, DC (2024)	One PSA test and digital rectal examination per year	All men
New York (2018)	Diagnostic screening for prostate cancer	Men over age 40 with a family history of prostate cancer; all men over age 50
Illinois (2022)	Prostate cancer screening and follow up diagnostic testing, including urinary analysis, serum biomarkers, and medical imaging, including MRI	African American men ages 40 and older; men with a family history of prostate cancer ages 40 and older; asymptomatic men ages 50 and older
Tennessee (2024)	Prostate cancer screenings for early detection	Men ages 40 to 49 who are at high risk, including African American men and men with a family history of prostate cancer; all men ages 50 and older; other men if a physician determines that early detection is medically necessary
Virginia (2025)	One PSA test and digital rectal examination in a 12-month period	Men ages 40 and older at high risk for prostate cancer; all men ages 50 and older

Kentucky (2024)	Any preventive screening, test, or procedure performed for the purpose of detecting cancer	Men ages 40 and older at higher risk, including men with multiple family members diagnosed with prostate cancer; men ages 45 and older at high risk, including African American men and men who have a first degree relative diagnosed with prostate cancer; men ages 50 and older at average risk
Delaware (2024)	Prostate screening for the detection and diagnosis of prostate cancer, including a digital rectal examination, PSA test, and associated laboratory work	Men ages 40 and older at higher risk, including men with more than one first degree relative diagnosed with prostate cancer; men ages 45 and older at high risk, including African American men and men who have a first degree relative diagnosed with prostate cancer; men ages 50 and older at average risk

*Source: Zero Prostate Cancer, "Saving Lives by Eliminating Costs of Early Detection of Prostate Cancer," 2025. Accessed 5/19/25. [Early Detection of Prostate Cancer: Eliminating Costs of Screening | ZERO Prostate Cancer](#)

The simplest way to group these states is by the age ranges and risk criteria used to determine the applicability of insurance coverage for prostate cancer screening. For three of the states and Washington, DC, commercial insurers are effectively required to provide prostate cancer screening coverage for all men, regardless of age or risk profile. Rhode Island, for example, mandates commercial insurance coverage for preventive screening examinations and laboratory tests for prostate cancer for asymptomatic men, as long as the testing is performed by an in-network provider.^{li} Similarly, Maryland requires commercial insurance coverage for preventive care screening services for prostate cancer, including a digital rectal exam and a PSA test, for all men 40 to 75 years of age.^{lii} Oregon Health Authority's Health Evidence Review Commission adopted a recommendation that requires commercial insurance coverage of PSA screening for prostate cancer for all men, regardless of prostate cancer risk.^{liii} Finally, Washington, DC law mandates commercial insurance coverage for one PSA test and digital rectal exam per year for all men.^{liv}

The prostate cancer screening laws of New York, Illinois, Tennessee, and Virginia require commercial insurance coverage for prostate cancer screening based on various risk factors, such as age, race, and family history. New York's law, for example, mandates coverage of diagnostic screening for prostate cancer for men over age 40 with a family history of prostate cancer; otherwise, commercial insurance coverage applies to all men over age 50.^{lv} Illinois's commercial insurance coverage law applies to African American men and men with a family history of prostate cancer ages 40 and over, as well as asymptomatic men ages 50 and over.^{lvi} The Illinois law further requires coverage for a broader range of benefits for prostate cancer screening and follow up

diagnostic testing as compared with other states, which additional screenings include urinary analysis, serum biomarkers, and medical imaging, including magnetic resonance imaging.^{lvii}

Tennessee uses a similar set of criteria to the Illinois law, requiring commercial insurance coverage of prostate cancer screenings for early detection for men ages 40 to 49 who are at high risk of prostate cancer, including African American men and men with a family history of prostate cancer, and for men 50 years and older who are not at high risk.^{lviii} Tennessee's law also requires coverage for men not included in those criteria if a physician determines that early detection is medically necessary. Virginia law mandates commercial insurance coverage for one PSA test and digital rectal examination in a 12-month period for men ages 40 and older who are at high risk for prostate cancer and for men ages 50 and older who are not at high risk.^{lix}

The last group of states, Kentucky and Delaware, make an even finer distinction in age groups and risk levels. Kentucky's law requires commercial insurance coverage for any preventive screening, test, or procedure performed for the purpose of detecting cancer, but divides the men to whom the coverage applies into three age groups, based on relative risk of prostate cancer. Coverage applies to men aged 40 and older if they have multiple family members diagnosed with prostate cancer. Coverage applies to men aged 45 and above if they are African American or have a first degree relative diagnosed with prostate cancer. For men at average risk of prostate cancer, coverage applies at age 50 and older.^{lx} Delaware's law mandates commercial insurance coverage for prostate screening for the detection and diagnosis of prostate cancer, including a digital rectal examination, PSA test, and associated laboratory work. The age and risk criteria that determine when the coverage provisions apply to Delaware men are nearly identical to those for Kentucky's prostate cancer screening mandate, dividing men into three groups. Commercial insurance coverage applies to men at ages 40 and older with the highest risk of prostate cancer, including those with more than one first degree relative diagnosed with prostate cancer (a slightly more restrictive criterion than Kentucky's "multiple family members diagnosed with prostate cancer"), at ages 45 and above for African American men and men who have a first degree relative diagnosed with prostate cancer, and at ages 50 and older for men at average risk.^{lxi} Although the specific parameters, including age and risk profile, used to determine insurance coverage varied by state, all of the laws discussed above prohibit the application of cost-sharing, such as deductibles, copays, or coinsurance, to covered prostate cancer screenings.

In comparison to these other states, S1796 does not differ from most of these states in terms of who is eligible for the benefit. However, New Jersey's bill is significantly broader in the list of services that are eligible for the mandate and for which no cost sharing is permitted. S1796 is most similar in its scope of benefits with the Illinois law, which is the only state law that, as would be provided under S1796, requires coverage for no-cost MRIs.

DISCUSSION

Studies have found that prostate cancer, when detected early, is usually highly treatable and has a high survival rate.^{lxii} In particular, early detection allows for an expanded range of treatment options, including the use of less-invasive treatments, enables faster recovery times, allows patients to maintain greater urinary and sexual function, can reduce the emotional burden on patients, and can result in a lower total cost of care when compared with detection at a more advanced stage.^{lxiii} Many patients with prostate cancer are asymptomatic, and, in the absence of routine screenings, may not learn they have prostate cancer until the disease has progressed to a more advanced stage, which can reduce treatment options, increase the cost of care, and result in more significant and lasting effects on the patient's medical condition and overall quality of life.^{lxiv} Although prostate cancer screenings can facilitate early detection and treatment, current screening methodologies can result in both false positives and false negatives, which can increase the stress and emotional burden on patients, including those who are ultimately found to be cancer-free.^{lxv}

Although New Jersey law currently requires specified carriers in certain markets to cover prostate cancer screenings for certain men, S1796, if enacted, would remove some age and risk-based distinctions from the coverage mandate, prohibit the application of cost-sharing to the coverage mandate, expand the coverage mandate to include associated laboratory work and follow-up testing, and expand the mandate to additional types of carriers.

Advocates for expanded insurance coverage for prostate cancer screenings suggest that expanded coverage will facilitate early detection and treatment, thereby reducing the overall cost of care when prostate cancer is detected.^{lxvi, lxvii} In addition, advocates have suggested that prohibiting the application of cost-sharing to prostate cancer screening coverage will remove certain financial barriers to access, enabling additional individuals to be screened who would not be otherwise.^{lxviii} Those advocates have also suggested that precluding cost-sharing for prostate cancer screenings will establish parity between prostate cancer screenings and certain other cancer screenings, such as screenings for breast cancer, for which cost sharing is already prohibited.^{lxix, lxx}

The American Cancer Society Cancer Action Network (CAN) wrote a memorandum in support of Washington, DC's proposed prostate screening law. Specifically, the CAN memo suggests, "[E]nabling cost-free access to screening and early detection of prostate cancer....will save lives, and could actually decrease the cost of providing health care for those impacted."^{lxxi}

Nine other states and Washington, DC have enacted laws prohibiting the application of cost-sharing for covered prostate cancer screenings. The coverage mandates established under these laws vary as to which populations are covered and under which circumstances, with some states requiring coverage for all men, regardless of risk factors, and others establishing age-based distinctions that factor in race and family history of cancer. The laws in those states can also be distinguished based on the specific tests and procedures that are subject to the coverage mandate, as well as the frequency at which the screenings are required to be covered. The language of these

state mandates also vary in the specific terminology used to describe the covered screenings, which distinctions may have a substantive effect on what specific services fall within the coverage mandate (*i.e.*, there may be differences depending on whether a given law applies to “preventive screenings,” “diagnostic screenings,” or “any preventive screening, test, or procedure performed for the purpose of detecting cancer”).

Although the stated purpose of many of these coverage mandates is to ensure early detection and treatment of prostate cancer, experts have cautioned that, because the most common screening methodologies for prostate cancer carry a risk of both false positives and false negatives, practitioners need to be aware of the potential limitations of those screening methodologies and be ready to take the steps needed to mitigate those limitations. Additionally, it should be noted that the current USPSTF guidelines assign a “C” grade to prostate cancer screenings for men ages 55 to 69 years and a “D” grade to prostate cancer screenings for men ages 70 and older; although it may be further noted that the Memorial Sloan Kettering Cancer Center has suggested that current screening recommendations may be based on an insufficient dataset. In other words, although some studies support modifying or removing certain age-based requirements for prostate cancer screening coverage, there is not universal support for doing so.

The Patient Protection and Affordable Care Act (ACA), Section 2713, amending the Public Health Services Act, as well as regulations implementing the ACA, and state law set forth at P.L.2019, c.360, currently require carriers to provide coverage for evidence-based preventive services that have an “A” or “B” recommendation rating from the USPSTF. As a result, because the current USPTF recommendations do not assign an A or B rating to prostate cancer screenings, the screenings are not required to be covered under the ACA’s general mandate on preventive services or New Jersey’s general mandate on preventive services. However, as noted, New Jersey already has statutory mandates requiring coverage for prostate cancer screening in certain markets and for certain purposes, and prostate cancer screenings are listed as an example of a preventive service for which coverage is required in the standard policy forms used by the Individual Health Coverage Program and the Small Employer Health Benefits Program.

Finally, some advocates have suggested that mandating commercial insurance coverage for prostate cancer screenings without cost-sharing makes these screenings more affordable and accessible. This may establish a coverage mandate that is on par with mandated screenings for other cancers, such as breast cancer, that similarly prohibit the application of cost-sharing.^{lxxii,lxxiii}

FINANCIAL IMPACT

Of the jurisdictions discussed above, in the “Other States” section, that have adopted a prostate cancer screening mandate that prohibits the application of cost sharing, four of those states and Washington, DC provided fiscal notes or financial impact statements analyzing the impact of those

mandates on insurance costs, examining either the impact to state budgets or to policy holders' premiums.

Washington, DC's fiscal impact statement is limited to a short description regarding funding for its proposed new law mandating coverage for one PSA test and one digital rectal examination per year, without cost-sharing. The document states, "Funds are sufficient in the fiscal year 2024 budget and fiscal year 2025 though fiscal year 2028 budget and financial plan to implement the bill...All health insurers operating in the District...already cover prostate cancer screenings."^{lxxiv} Virginia's fiscal statement assessing the budget impact of mandating coverage for one PSA test and one digital rectal examination per year on health carriers and the health care coverage plan for state employees, as well as the state's Medicaid program, was summarized in one sentence, "The proposed legislation is not expected to have a state fiscal impact."^{lxxv}

Tennessee's Fiscal Review Committee produced a fiscal note analyzing the impact of extending commercial insurance coverage for prostate cancer screenings for early detection beyond men ages 50 and older to men 40 to 49 years of age at high risk of prostate cancer, and to other men if a physician determines that early detection is medically necessary. Tennessee's law also eliminated all cost-sharing provisions for these prostate cancer screenings. The analysis estimated no fiscal impact on the State Group Insurance Program and found any fiscal impact on Tennessee's Department of Commerce and Insurance was "estimated to be not significant."^{lxxvi}

Maryland provided several analyses of the fiscal and insurance premium impacts of its prostate cancer screening law, which would eliminate all cost-sharing provisions in extending coverage for preventive care screening services, including a PSA test and digital rectal examination, to all men 40 to 75 years of age. The Department of Legislative Services produced a fiscal and policy note, reporting the following fiscal impacts, "Potential minimal increase for the State Employee and Retiree Health and Welfare Benefits Program...Potential increase in expenditures for local governments that purchase fully insured insurance plans..."^{lxxvii} The analysis also estimated potentially meaningful impacts for small businesses, to the extent that the elimination of cost-sharing could increase costs for small group insurance carriers.^{lxxviii}

The Maryland Health Care Commission ("Commission") provided a more detailed analysis of the insurance premium impacts of the prostate screening bill. The Commission analysis "included the fully insured individual market, small group market, and large group market (including the Federal Employees Health Benefits Program)."^{lxxix} Across all of these markets, "The Commission estimates that the elimination of cost-sharing will add about \$0.03 per member per month (PMPM) to fully insured health care premiums (or about \$0.35 per year)...in Maryland."^{lxxx} An earlier cost analysis by the Commission found "the estimated cost for eliminating the member cost-sharing is about 0.01% of premium across all markets (individual, small group, and fully-insured large group)."^{lxxxii} The Commission also stated its belief that the elimination of cost-sharing would not "fuel excessive demand" for PSA testing, "because of the emphasis on shared decision making" in assessing the benefit of PSA screening.^{lxxxii}

Kentucky provided four analyses of the projected impacts of its law requiring commercial insurance coverage for any preventive screening, test, or procedure performed for the purpose of detecting cancer. This insurance coverage mandate was extended to men 40 years and older at highest risk of prostate cancer, to men aged 45 years and older at high risk, and to men aged 50 years and older at average risk, while also eliminating all cost-sharing provisions. The Kentucky Department of Insurance analyzed the financial impacts of the legislation on all fully insured policies for all health benefits plans, excluding Medicaid and the state employees' program. That financial impact statement found that the expanded requirement "is not expected to materially increase premiums...." and "is not expected to materially increase the total cost of health care in the Commonwealth...."^{lxxxiii} The expanded requirements were also not expected to materially increase the administrative costs of the carriers.^{lxxxiv} The financial impact statement also noted, "It is acknowledged that there is a potential for long-term savings due to increased affordability and accessibility to cancer screenings which could lead to earlier detection of cancer."^{lxxxv} However, the report advised that this analysis was beyond the time and resources available to the authors.

A second analysis of the Kentucky legislation examined the impact of the expanded coverage mandate on local governments. The Kentucky Legislative Research Commission (LRC) reported the expanded mandate would "have no fiscal impact on the majority of cities since the health insurance they offer includes preventive care."^{lxxxvi} For those cities that offer health insurance plans without preventive screening coverage, "The bill would have an indeterminable but negative short term fiscal impact on premiums...." The LRC indicated that, while it did not have sufficient data to make an informed estimate of the potential increase in premiums to pay for the additional preventive services, "[P]reventive services generally result in long term cost savings because early detection reduces the potential for more costly treatments in the future."^{lxxxvii}

The LRC also prepared separate actuarial analyses on behalf of the Kentucky Public Pensions Authority (KPPA) and the Judicial Form Retirement System (JFRS). With regard to the projected effects on the KPPA, the LRC found that the new coverage mandate "will not increase or decrease benefits, nor will it increase or decrease the participation in benefits, in any of the retirement systems administered by the [KPPA]."^{lxxxviii} The LRC also reported that new law would not change the actuarial accrued liability of any of the systems administered by KPPA.^{lxxxix} Finally, the LRC found there "may be an increase in employer costs if the inclusion of preventive cancer screenings causes an increase in insurance premiums for the plans provided through KPPA...."^{xc} The LRC's actuarial analysis for the JFRS reported the same findings.^{xc}

An additional consideration is that the federal Patient Protection and Affordable Care Act requires states to defray the cost of any health insurance benefit mandate enacted after December 31, 2011, that is part of an insurance plan sold on a state exchange that is in addition to the state's essential health benefits (EHBs) and related to specific care, treatment, or services (P.L. 111-148 § 1311(d)(3) & 45 CFR 155.170). The state must then defray the cost of the additional mandates by making the appropriate payment directly to an enrollee or to the insurer on the enrollee's behalf

(45 CFR 155.170). A 2017 federal final rule (§ 19) changed the entity responsible for identifying mandates and receiving excess cost reports from the state's exchange to the state. Defrayment does not apply to the large group market. For more information on State-required benefits, please refer to this CMS FAQ on Defrayal of State Additional Required Benefits.^{xcii} As part of the HHS Notice of Benefit and Payment Parameters for 2025, for plan years beginning on or after January 1, 2027, CMS is proposing revisions to the standards for state selection of EHB-benchmark plans to address long-standing requests from states to improve, and reduce the burden of, the EHB-benchmark plan update process.^{xciii} The process of updating the state's EHB-benchmark plan could create a pathway to adding benefits to the benchmark plan that may not trigger defrayal provided certain parameters are met. Thus, although this is a state-by-state analysis and no such analysis has been performed for New Jersey, a coverage mandate for prostate cancer screening without cost sharing may trigger the federal defrayment requirements.

CONCLUSION

The prostate cancer screening recommendations and guidelines from leading national entities differ. The USPSTF does not recommend screening for men younger than 55 years of age, recommends that men and their healthcare providers balance considerations of potential benefits and harms from screening for men between the ages of 55 and 69 years, and recommends against screening for men 70 years and older. ACS guidelines recommend that men at higher risk of prostate cancer, due to personal demographics or family history, begin discussions with their healthcare providers at younger ages and recommend screening using a PSA test.

The medical evidence shows that earlier detection of prostate cancer results in significantly higher survival rates compared with patients whose cancer is detected at a more advanced stage. Studies suggest the treatment of prostate cancer in its earlier stages also leads to fewer side effects and better quality of life. The cost of care for treating prostate cancer at a more advanced stage is significantly higher, as studies have found the cost of treating stage 4 prostate cancer is up to 7 times more expensive than the cost of treating stage 1 prostate cancer.

S1796 and the enacted laws discussed in this report prohibit the application of cost-sharing to prostate cancer screenings subject to the coverage mandate, the purpose of which is generally attributed to the goal of increasing access to screenings, improving screening rates, and lowering or removing potential barriers from the decision to screen for prostate cancer.

Although some state financial or fiscal impact statements identified the possibility of higher costs or premiums in some insurance markets resulting from a prohibition on cost-sharing for prostate cancer screenings, none found the potential costs to be prohibitive. Most analyses found no meaningful increases in healthcare costs, insurance premiums, or administrative expenditures as a result of these mandated changes in coverage. Several fiscal impact analyses additionally predicted that states could expect long-term savings as a result of improving the affordability and

accessibility of screening, which in turn would result in prostate cancer being detected and diagnosed at earlier stages, when the disease is less costly to treat.

On the other hand, of the enacted laws discussed above, only the Illinois law enacted coverage of services that appears to be comparable to the services that would be subject to the coverage mandate that would be established under S1796. Like S1796, Illinois' prostate screening law requires coverage of all screening tests and procedures, as well as follow up services including, but not limited to, urinary analysis, serum biomarkers, and medical imaging, including, but not limited to, magnetic resonance imaging, for men at younger ages at higher risk levels. The Illinois prostate cancer screening law did not require a fiscal impact statement, so no detailed financial analysis of the law most comparable to S1796 exists. As a result, the cost of coverage for this broader range of services with no cost sharing, especially follow-up services such as MRIs, will likely be higher than has been observed under other state laws providing expanded coverage for prostate cancer screenings.

In addition to expanding the scope of the existing statutory prostate cancer coverage mandate to apply to a broader age range, remove certain risk-factor-based distinctions, expand the scope of services covered under the mandate, and prohibit the application of cost-sharing, S1796 would expand the coverage mandate to additional insurance markets, including the individual insurance market, the Individual Health Coverage and Small Employer Health Benefits Programs, and the State Health Benefit Program and School Employees' Health Benefits Program. To the extent these markets do not already provide coverage for prostate cancer screenings, or to the extent that existing coverage in those markets would be expanded, there may be a fiscal impact to those markets. As discussed above, the effect on premiums in those markets may be *de minimis*, and there is the potential that increased costs resulting from increased utilization and a restriction on cost-sharing will be offset by cost savings resulting from earlier treatment interventions. Although studies suggest the financial effects of an expanded prostate cancer screening mandate and a prohibition on cost-sharing on insurance costs are likely to be minimal, it is not possible at this juncture to predict how S1796 would affect prostate cancer screening utilization or either increase or decrease the costs of insurance coverage.

ENDNOTES

ⁱ Mayo Clinic, "Prostate Cancer, Symptoms & Causes," February 20, 2025. Accessed 5/7/25. [Prostate cancer - Symptoms and causes - Mayo Clinic](#)

ⁱⁱ *Ibid.*

ⁱⁱⁱ Memorial Sloan Kettering Cancer Center, "Prostate Cancer Signs & Symptoms," 2025. Accessed 5/13/25. [Prostate Cancer Signs & Symptoms | Memorial Sloan Kettering Cancer Center](#)

^{iv} CDC, "Screening for Prostate Cancer," August 27, 2024. Accessed 5/7/25. [Screening for Prostate Cancer | Prostate Cancer | CDC](#)

^v Mayo Clinic, "Prostate Cancer Screening: Should You Get Screened?," December 17, 2024. Accessed 5/7/25. [Prostate cancer screening: Should you get screened? - Mayo Clinic](#)

^{vi} Mayo Clinic 2024, *op cit.*

^{vii} *Ibid.*

^{viii} Mayo Clinic, "Prostate Cancer, Diagnosis & Treatment," February 20, 2025. Accessed 5/7/25. [Prostate cancer - Diagnosis and treatment - Mayo Clinic](#)

^{ix} *Ibid.*

^x *Ibid.*

^{xi} *Ibid.*

^{xii} Zero Prostate Cancer, "Early Detection Saves Lives: Screening and PSA Test," 2025. Accessed 5/30/25. [Prostate Cancer Early Detection: Why It Matters & How to Get Screened | ZERO Prostate Cancer](#)

^{xiii} American Cancer Society, "Survival Rates for Prostate Cancer," January 16, 2025. Accessed 5/30/25. [What Are the Survival Rates for Prostate Cancer? | American Cancer Society](#)

^{xiv} *Ibid.*

^{xv} Zero Prostate Cancer, *op cit.*

^{xvi} *Ibid.*

^{xvii} Mayo Clinic Symptoms & Causes 2025, *op cit.*

^{xviii} *Ibid.*

^{xix} American Cancer Society, "American Cancer Society Recommendations for Prostate Cancer Early Detection," November 22, 2023. Accessed 5/7/25. [American Cancer Society Recommendations for Prostate Cancer Early Detection | American Cancer Society](#)

^{xx} *Ibid.*

^{xxi} *Ibid.*

^{xxii} *Ibid.*

^{xxiii} *Ibid.*

^{xxiv} United States Preventive Services Task Force, “Prostate Cancer: Screening,” May 8, 2018. Accessed 5/7/25. [Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce](#)

^{xxv} *Ibid.*

^{xxvi} United States Preventive Services Task Force, “Grade Definitions”, October 2018. Accessed 6/10/25. [Grade Definitions | United States Preventive Services Taskforce](#)

^{xxvii} *Ibid.*

^{xxviii} USPSTF, May 2018, *op cit.*

^{xxix} Mayo Clinic, 2024, *op cit.*

^{xxx} *Ibid.*

^{xxxi} *Ibid.*

^{xxxii} Julie Grisham, “Myths About PSA Tests and Prostate Cancer Screening,” Memorial Sloan Kettering Cancer Center, April 8, 2024. Accessed 5/20/25. [Myths About PSA Tests and Prostate Cancer Screening | Memorial Sloan Kettering Cancer Center](#)

^{xxxiii} Zero Prostate Cancer, “Saving Lives by Eliminating Costs of Early Detection of Prostate Cancer,” 2025. Accessed 5/7/25. [Early Detection of Prostate Cancer: Eliminating Costs of Screening | ZERO Prostate Cancer](#)

^{xxxiv} *Ibid.*

^{xxxv} Memorial Sloan Kettering Cancer Center, “ Why Black Men Should Consider Earlier Screening for Prostate Cancer,” January 17, 2025. Accessed 5/20/25. [Why Black Men Should Consider Earlier Screening for Prostate Cancer | Memorial Sloan Kettering Cancer Center](#)

^{xxxvi} *Ibid.*

^{xxxvii} *Ibid.*

^{xxxviii} *Ibid.*

^{xxxix} Garraway, Isla P., Carlsson, Sigrid V., Nyame, Yaw A., and *et al.*, “Prostate Cancer Foundation Screening Guidelines for Black Men in the United States,” The New England Journal of Medicine Evidence, Volume 3(5), April 23, 2024. Accessed 5/20/25. [Prostate Cancer Foundation Screening Guidelines for Black Men in the United States | NEJM Evidence](#)

^{xl} Collins-McNaughton, Mary, Fowler, Floyd J., Caubet, Jean-Francois, and *et al.*, “Psychological Effects of a Suspicious Prostate Cancer Screening Test Followed by a Benign Biopsy Result,” The American Journal of Medicine, Volume 117(10), November 15, 2004. Accessed 5/7/25. [Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result - The American Journal of Medicine](#)

^{xli} *Ibid.*

^{xlii} *Ibid.*

^{xliii} *Ibid.*

^{xliv} *Ibid.*

^{xlv} Reddy, Sheila R., Broder, Michael S., Chang, Eunice, Paydar, Caleb, and *et al.*, “Cost of Cancer Management by Stage at Diagnosis among Medicare Beneficiaries,” *Current Medical Research and Opinion*, Volume 38(8), April 20, 2022. Accessed 5/30/25. [Full article: Cost of cancer management by stage at diagnosis among Medicare beneficiaries](#)

^{xlvi} *Ibid.*

^{xlvii} *Ibid.*

^{xlviii} *Ibid.*

^{lix} Zero Prostate Cancer, “State-level Access to Early Detection,” 2025. Accessed 5/19/25. [ZERO Prostate Cancer | State Policy Action Center](#)

^l State of Rhode Island, “2021 – S0383 As Amended,” January 2021. Accessed 5/19/25. [Rhode Island-2021-S0383-Amended.pdf](#)

^{li} Justia, “2024 Rhode Island General Laws, Title 27 – Insurance,” 2024. Accessed 5/19/25. [General Laws of Rhode Island Section 27-18-58. \(2024\) - Prostate and colorectal examinations — Coverage mandated — The Maryellen Goodwin Colorectal Cancer Screening Act. :: 2024 Rhode Island General Laws :: U.S. Codes and Statutes :: U.S. Law :: Justia](#)

^{lii} Chapter 343 (Maryland House Bill 852), “An Act Concerning Health Insurance – Prostate Cancer Screening Services – Prohibiting Cost-Sharing,” 2020. Accessed 5/19/25. [2020 Regular Session - House Bill 852 Chapter](#)

^{liii} Zero Prostate Cancer, “Saving Lives by Eliminating Costs of Early Detection of Prostate Cancer,” 2025. Accessed 5/19/25. [Early Detection of Prostate Cancer: Eliminating Costs of Screening | ZERO Prostate Cancer](#)

^{liv} Washinton, DC, “An Act in the Council of the District of Columbia,” 2024. Accessed 5/19/24. [B25-0229-Enrollment1.pdf](#)

^{lv} Zero Prostate Cancer, “New York 2024 – Prostate Cancer Facts & Statistics,” April 29, 2024. Accessed 5/28/25. [New York 2024 - Prostate Cancer Facts & Statistics | ZERO Prostate Cancer](#)

^{lvi} Illinois General Assembly, “Public Act 102-1073, HB5318 Enrolled,” 2022. Accessed 5/27/25. [102-1073](#)

^{lvii} Illinois General Assembly, “Public Act 102-1073, HB5318 Enrolled,” 2022. Accessed 5/27/25. [102-1073](#)

^{lviii} State of Tennessee, “Public Chapter No. 1003, House Bill No. 2954,” 2024. Accessed 5/19/25. [pc1003.pdf](#)

^{lix} Virginia Acts of Assembly – 2025 Session, “Chapter 246,” Approved March 21, 2025. Accessed 2/27/25. [1072890.PDF](#)

^{lx} Legislative Research Commission (Kentucky), *op cit.*

^{lxi} Legislative Council, General Assembly, State of Delaware, “Laws of Delaware, Volume 84, Chapter 511, 152nd General Assembly, Formerly House Substitute No. 1 for House Bill 302,” 2024. Accessed 5/27/24. [chp511.pdf](#)

^{lxii} American Cancer Society, January 16, 2025, *op cit.*

^{lxiii} *Ibid.*

^{lxiv} *Ibid.*

^{lxv} Collins-McNaughton, *op cit.*

^{lxvi} *Ibid.*

^{lxvii} State of Tennessee, *op cit.*

^{lxviii} Ricks, Delthia, “New York State Health Insurers Now Required to Cover PSA Blood Test,” Medical Xpress, February 27, 2019. Accessed 5/19/25.

[New York State health insurers now required to cover PSA blood test](#)

^{lxix} Zero Prostate Cancer, “Breaking: Financial Barriers to Prostate Cancer Screenings Removed for Maryland Men,” May 7, 2020. Accessed 5/19/25.

[BREAKING: Financial Barriers to Prostate Cancer Screenings Removed for Maryland Men | ZERO Prostate Cancer](#)

^{lxx} Ricks, *op cit.*

^{lxxi} American Cancer Society Cancer Action Network, “[Memorandum in Support of B25-0229],” September 28, 2023. Accessed 5/19/25. [B25-0229-Committee_Report1.pdf](#)

^{lxxii} Zero Prostate Cancer, May 7, 2020, *op cit.*

^{lxxiii} Ricks, *op cit.*

^{lxxiv} Government of the District of Columbia, Office of the Chief Financial Officer, “Memorandum: Fiscal Impact Statement – Cost-Free Coverage for Prostate Cancer Screening Amendment Act of 2024,” July 1, 2024. Accessed 5/30/25. [FIS Cost-Free Coverage for Prostate Cancer Screening.pdf](#)

^{lxxv} Department of Planning and Budget (Virginia), 2025 General Assembly Session, “State Fiscal Impact Statement, Health Insurance; Coverage Requirements for Prostate Cancer Screenings,” February 14, 2025. Accessed 5/19/25. [1052508.PDF](#)

^{lxxvi} Tennessee General Assembly, Fiscal Review Committee, “Fiscal Note, HB 2954 – SB 2883,” March 7, 2024. Accessed 5/19/25. [HB2954.pdf](#)

^{lxxvii} Department of Legislative Services, Maryland General Assembly, 2020 Session, “Fiscal and Policy Note, Third Reader – Revised, House Bill 852,” June 2, 2020. Accessed 5/19/25.

[2020 Regular Session - Fiscal and Policy Note for House Bill 852](#)

^{lxxviii} *Ibid.*

^{lxxix} State of Maryland, Maryland Health Care Commission, “Re: SB 661 – Health Insurance --- Prostate Cancer Screening – Prohibiting Cost-Sharing – Information,” February 24, 2020. Accessed 5/27/25.

[2726_02262020_104451-602.pdf](#)

^{lxxx} *Ibid.*

^{lxxxi} *Ibid.*

^{lxxxii} *Ibid.*

^{lxxxiii} Kentucky Department of Insurance, “Financial Impact Statement,” March 4, 2024. Accessed 5/19/25. [HM.pdf](#)

^{lxxxiv} *Ibid.*

^{lxxxv} *Ibid.*

^{lxxxvi} Kentucky Legislative Research Commission, 2024 Regular Session, “Local Government Mandate Statement,” March 1, 2024. Accessed 5/19/25. [LM.pdf](#)

^{lxxxvii} *Ibid.*

^{lxxxviii} Kentucky Legislative Research Commission, Office of Fiscal Statement Review, “Kentucky Public Pension Authority, Actuarial Analysis House Bill 52 (2024 RS BR 6) – GA Version,” March 1, 2024. Accessed 5/19/25. [AA.pdf](#)

^{lxxxix} *Ibid.*

^{xc} *Ibid.*

^{xc i} *Ibid.*

^{xcii} Federal Register, “Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2025; Updating Section 1332 Waiver Public Notice Procedures; Medicaid; Consumer Operated and Oriented Plan (CO-OP) Program; and Basic Health Program,” April 15, 2024. Accessed 2/7/25. <https://www.federalregister.gov/documents/2024/04/15/2024-07274/patient-protection-and-affordable-care-act-hhs-notice-of-benefit-and-payment-parameters-for-2025>.

^{xciii} *Ibid.*

SENATE, No. 1796

STATE OF NEW JERSEY

222nd LEGISLATURE

PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION

Sponsored by:

Senator TROY SINGLETON

District 7 (Burlington)

Senator BRIAN P. STACK

District 33 (Hudson)

Co-Sponsored by:

**Senators Gopal, Greenstein, A.M.Bucco, Amato, Lagana, Burgess, Beach,
Turner, Ruiz, Johnson and Zwicker**

SYNOPSIS

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

CURRENT VERSION OF TEXT

Introduced Pending Technical Review by Legislative Counsel.



1 AN ACT concerning health insurance coverage for prostate cancer
2 screening and amending P.L.1996, c.125 and supplementing
3 various parts of the statutory law.
4

5 **BE IT ENACTED** by the Senate and General Assembly of the State
6 of New Jersey:
7

8 1. Section 1 of P.L.1996, c.125 (C.17:48E-35.13) is amended
9 to read as follows:.

10 1. a. No health service corporation contract providing hospital
11 or medical expense benefits **for groups with greater than 49**
12 **persons** shall be delivered, issued, executed or renewed in this
13 State, or approved for issuance or renewal in this State by the
14 Commissioner of Insurance on or after the effective date of **this**
15 **act** P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the contract
16 provides benefits to any named subscriber or other person covered
17 thereunder for expenses incurred in conducting an annual
18 **medically recognized diagnostic examination including, but not**
19 **limited to, a digital rectal examination and a prostate-specific**
20 **antigen test for men age 50 and over who are asymptomatic and for**
21 **men age 40 and over with a family history of prostate cancer or**
22 **other prostate cancer risk factors** prostate cancer screening.

23 The benefits shall be provided to the same extent as for any other
24 medical condition under the contract except that no deductible,
25 coinsurance, copayment, or any other cost-sharing requirement on
26 the benefits shall be imposed for men who are between 40 and 75
27 years of age.

28 This section shall apply to all health service corporation
29 contracts in which the health service corporation has reserved the
30 right to change the premium.

31 b. As used in this section:

32 “Prostate cancer screening” means medically viable methods for
33 the detection and diagnosis of prostate cancer, which includes a
34 digital rectal exam and the prostate-specific antigen test and
35 associated laboratory work. “Prostate cancer screening” shall also
36 include subsequent follow up testing as direct by a health care
37 provider, including, but not limited to:

38 (1) urinary analysis;

39 (2) serum biomarkers;

40 (3) medical imaging, including, but not limited to, magnetic
41 resonance imaging.

42 (cf: P.L.1996, c.125, s.1)

EXPLANATION – Matter enclosed in bold-faced brackets **[thus]** in the above bill is not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

1 2. Section 2 of P.L.1996, c.125 (C.17:48-6p) is amended to
2 read as follows:

3 2. a. No hospital service corporation contract providing
4 hospital or medical expense benefits **【for groups with greater than**
5 **49 persons】** shall be delivered, issued, executed or renewed in this
6 State, or approved for issuance or renewal in this State by the
7 Commissioner of Insurance on or after the effective date of **【this**
8 **act】** P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the contract
9 provides benefits to any named subscriber or other person covered
10 thereunder for expenses incurred in conducting an annual
11 **【medically recognized diagnostic examination including, but not**
12 **limited to, a digital rectal examination and a prostate-specific**
13 **antigen test for men age 50 and over who are asymptomatic and for**
14 **men age 40 and over with a family history of prostate cancer or**
15 **other prostate cancer risk factors】**prostate cancer screening.

16 The benefits shall be provided to the same extent as for any other
17 medical condition under the contract except that no deductible,
18 coinsurance, copayment, or any other cost-sharing requirement on
19 the benefits shall be imposed for men who are between 40 and 75
20 years of age.

21 This section shall apply to all hospital service corporation
22 contracts in which the hospital service corporation has reserved the
23 right to change the premium.

24 b. As used in this section:

25 “Prostate cancer screening” means medically viable methods for
26 the detection and diagnosis of prostate cancer, which includes a
27 digital rectal exam and the prostate-specific antigen test and
28 associated laboratory work. “Prostate cancer screening” shall also
29 include subsequent follow up testing as direct by a health care
30 provider, including, but not limited to:

31 (1) urinary analysis;

32 (2) serum biomarkers;

33 (3) medical imaging, including, but not limited to, magnetic
34 resonance imaging.

35 (cf: P.L.1996, c.125, s.2)

36

37 3. Section 3 of P.L.1996, c.125 (C.17:48A-7n) is amended to
38 read as follows:

39 3. a. No medical service corporation contract providing
40 hospital or medical expense benefits **【for groups with greater than**
41 **49 persons】** shall be delivered, issued, executed or renewed in this
42 State, or approved for issuance or renewal in this State by the
43 Commissioner of Insurance on or after the effective date of **【this**
44 **act】** P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the contract
45 provides benefits to any named subscriber or other person covered
46 thereunder for expenses incurred in conducting an annual
47 **【medically recognized diagnostic examination including, but not**

1 limited to, a digital rectal examination and a prostate-specific
2 anitgen test for men age 50 and over who are asymptomatic and for
3 men age 40 and over with a family history of prostate cancer or
4 other prostate cancer risk factors **】** prostate cancer screening.

5 The benefits shall be provided to the same extent as for any other
6 medical condition under the contract except that no deductible,
7 coinsurance, copayment, or any other cost-sharing requirement on
8 the benefits shall be imposed for men who are between 40 and 75
9 years of age.

10 This section shall apply to all medical service corporation
11 contracts in which the medical service corporation has reserved the
12 right to change the premium.

13 b. As used in this section:

14 “Prostate cancer screening” means medically viable methods for
15 the detection and diagnosis of prostate cancer, which includes a
16 digital rectal exam and the prostate-specific antigen test and
17 associated laboratory work. “Prostate cancer screening” shall also
18 include subsequent follow up testing as direct by a health care
19 provider, including, but not limited to:

20 (1) urinary analysis;

21 (2) serum biomarkers;

22 (3) medical imaging, including, but not limited to, magnetic
23 resonance imaging.

24 (cf: P.L.1996, c.125, s.3)

25

26 4. Section 4 of P.L.1996, c.125 (C.17B:27-46.1o) is amended
27 to read as follows:

28 4. a. No group health insurance policy providing hospital or
29 medical expense benefits **【**for groups with greater than 49 persons**】**
30 shall be delivered, issued, executed or renewed in this State, or
31 approved for issuance or renewal in this State by the Commissioner
32 of Insurance on or after the effective date of **【**this act**】** P.L.1996,
33 c.125 (C.17:48E-35.13 et al.), unless the policy provides benefits to
34 any named insured or other person covered thereunder for expenses
35 incurred in conducting an annual **【**medically recognized diagnostic
36 examination including, but not limited to, a digital rectal
37 examination and a prostate-specific antigen test for men age 50 and
38 over who are asymptomatic and for men age 40 and over with a
39 family history of prostate cancer or other prostate cancer risk
40 factors **】** prostate cancer screening.

41 The benefits shall be provided to the same extent as for any other
42 medical condition under the policy except that no deductible,
43 coinsurance, copayment, or any other cost-sharing requirement on
44 the benefits shall be imposed for men who are between 40 and 75
45 years of age.

1 This section shall apply to all group health insurance policies in
2 which the health insurer has reserved the right to change the
3 premium.

4 b. As used in this section:

5 “Prostate cancer screening” means medically viable methods for
6 the detection and diagnosis of prostate cancer, which includes a
7 digital rectal exam and the prostate-specific antigen test and
8 associated laboratory work. “Prostate cancer screening” shall also
9 include subsequent follow up testing as direct by a health care
10 provider, including, but not limited to:

11 (1) urinary analysis;

12 (2) serum biomarkers;

13 (3) medical imaging, including, but not limited to, magnetic
14 resonance imaging.

15 (cf: P.L.1996, c.125, s.4)

16
17 5. Section 5 of P.L.1996, c.125 (C.26:2J-4.13) is amended to
18 read as follows:

19 5. a. A certificate of authority to establish and operate a health
20 maintenance organization in this State shall not be issued or
21 continued by the Commissioner of Health on or after the effective
22 date of [this act] P.L.1996, c.125 (C.17:48E-35.13 et al.) unless the
23 health maintenance organization provides health care services to
24 any enrollee which include an annual [medically recognized
25 diagnostic examination including, but not limited to, a digital rectal
26 examination and a prostate-specific antigen test for men age 50 and
27 over who are asymptomatic and for men age 40 and over with a
28 family history of prostate cancer or other prostate cancer risk
29 factors] prostate cancer screening.

30 The health care services shall be provided to the same extent as
31 for any other medical condition under the contract except that no
32 deductible, coinsurance, copayment, or any other cost-sharing
33 requirement on the services shall be imposed for men who are
34 between 40 and 75 years of age.

35 The provisions of this section shall apply to all contracts for
36 health care services by health maintenance organizations under
37 which the right to change the schedule of charges for enrollee
38 coverage is reserved.

39 b. As used in this section:

40 “Prostate cancer screening” means medically viable methods for
41 the detection and diagnosis of prostate cancer, which includes a
42 digital rectal exam and the prostate-specific antigen test and
43 associated laboratory work. “Prostate cancer screening” shall also
44 include subsequent follow up testing as directed by a health care
45 provider, including, but not limited to:

46 (1) urinary analysis;

47 (2) serum biomarkers;

1 (3) medical imaging, including, but not limited to, magnetic
2 resonance imaging.

3 (cf: P.L.1996, c.125, s.5)

4
5 6. (New section) a. Every individual health insurance policy
6 that provides hospital or medical expense benefits and is delivered,
7 issued, executed or renewed in this State pursuant to chapter 26 of
8 Title 17B of the New Jersey Statutes, or approved for issuance or
9 renewal in this State by the Commissioner of Banking and
10 Insurance, on or after the effective date of this act shall provide
11 coverage for an annual prostate cancer screening.

12 The benefits shall be provided to the same extent as for any other
13 medical condition under the contract except that no deductible,
14 coinsurance, copayment, or any other cost-sharing requirement on
15 the services shall be imposed for men who are between 40 and 75
16 years of age.

17 The provisions of this section shall apply to all policies in which
18 the insurer has reserved the right to change the premium.

19 b. As used in this section:

20 “Prostate cancer screening” means medically viable methods for
21 the detection and diagnosis of prostate cancer, which includes a
22 digital rectal exam and the prostate-specific antigen test and
23 associated laboratory work. “Prostate cancer screening” shall also
24 include subsequent follow up testing as direct by a health care
25 provider, including, but not limited to:

26 (1) urinary analysis;

27 (2) serum biomarkers;

28 (3) medical imaging, including, but not limited to, magnetic
29 resonance imaging.

30
31 7. (New section) a. Every individual health benefits plan that
32 provides hospital or medical expense benefits and is delivered,
33 issued, executed or renewed in this State pursuant to P.L.1992,
34 c.161 (C.17B:27A-2 et seq.) or approved for issuance or renewal in
35 this State on or after the effective date of this act shall provide
36 benefits for an annual prostate cancer screening.

37 The benefits shall be provided to the same extent as for any other
38 medical condition under the contract except that no deductible,
39 coinsurance, copayment, or any other cost-sharing requirement on
40 the services shall be imposed for men who are between 40 and 75
41 years of age.

42 The provisions of this section shall apply to all health benefits
43 plans in which the carrier has reserved the right to change the
44 premium.

45 b. As used in this section:

46 “Prostate cancer screening” means medically viable methods for
47 the detection and diagnosis of prostate cancer, which includes a
48 digital rectal exam and the prostate-specific antigen test and

1 associated laboratory work. "Prostate cancer screening" shall also
2 include subsequent follow up testing as direct by a health care
3 provider, including, but not limited to:

- 4 (1) urinary analysis;
- 5 (2) serum biomarkers;
- 6 (3) medical imaging, including, but not limited to, magnetic
7 resonance imaging.

8
9 8. (New section) a. Every small employer health benefits plan
10 that provides hospital or medical expense benefits and is delivered,
11 issued, executed or renewed in this State pursuant to P.L.1992,
12 c.162 (C.17B:27A-17 et seq.) or approved for issuance or renewal
13 in this State on or after the effective date of this act shall provide
14 benefits for an annual prostate cancer screening.

15 The benefits shall be provided to the same extent as for any other
16 medical condition under the contract except that no deductible,
17 coinsurance, copayment, or any other cost-sharing requirement on
18 the services shall be imposed for men who are between 40 and 75
19 years of age.

20 The provisions of this section shall apply to all health benefits
21 plans in which the carrier has reserved the right to change the
22 premium.

23 b. As used in this section:

24 "Prostate cancer screening" means medically viable methods for
25 the detection and diagnosis of prostate cancer, which includes a
26 digital rectal exam and the prostate-specific antigen test and
27 associated laboratory work. "Prostate cancer screening" shall also
28 include subsequent follow up testing as direct by a physician,
29 including, but not limited to:

- 30 (1) urinary analysis;
- 31 (2) serum biomarkers;
- 32 (3) medical imaging, including, but not limited to, magnetic
33 resonance imaging.

34
35 9. (New section) a. The State Health Benefits Commission
36 shall ensure that every contract purchased by the commission on or
37 after the effective date of this act that provides hospital or medical
38 expense benefits shall provide coverage for an annual prostate
39 cancer screening.

40 The benefits shall be provided to the same extent as for any other
41 medical condition under the contract except that no deductible,
42 coinsurance, copayment, or any other cost-sharing requirement on
43 the services shall be imposed for men who are between 40 and 75
44 years of age.

45 b. As used in this section:

46 "Prostate cancer screening" means medically viable methods for
47 the detection and diagnosis of prostate cancer, which includes a
48 digital rectal exam and the prostate-specific antigen test and

1 associated laboratory work. “Prostate cancer screening” shall also
2 include subsequent follow up testing as direct by a health care
3 provider, including, but not limited to:

- 4 (1) urinary analysis;
- 5 (2) serum biomarkers;
- 6 (3) medical imaging, including, but not limited to, magnetic
7 resonance imaging.

8
9 10. (New section) a. The School Employees’ Health Benefits
10 Commission shall ensure that every contract purchased by the
11 commission on or after the effective date of this act that provides
12 hospital or medical expense benefits shall provide coverage for an
13 annual prostate cancer screening.

14 The benefits shall be provided to the same extent as for any other
15 medical condition under the contract except that no deductible,
16 coinsurance, copayment, or any other cost-sharing requirement on
17 the services shall be imposed for men who are between 40 and 75
18 years of age.

19 b. As used in this section:

20 “Prostate cancer screening” means medically viable methods for
21 the detection and diagnosis of prostate cancer, which includes a
22 digital rectal exam and the prostate-specific antigen test and
23 associated laboratory work. “Prostate cancer screening” shall also
24 include subsequent follow up testing as direct by a health care
25 provider, including, but not limited to:

- 26 (1) urinary analysis;
- 27 (2) serum biomarkers;
- 28 (3) medical imaging, including, but not limited to, magnetic
29 resonance imaging.

30
31 11. This act shall take effect on the 90th day next following the
32 date of enactment and shall apply to all contracts and policies
33 delivered, issued, executed, or renewed on or after that date.

34

35

36 STATEMENT

37

38 As amended, this bill requires health, hospital, and medical
39 service corporations, health maintenance organizations, and
40 commercial group health insurers to provide coverage for an annual
41 prostate cancer screening without cost sharing for men who are
42 between 40 and 75 years of age. Under current law, these health
43 insurance carriers are required only to provide coverage for an
44 annual medically recognized diagnostic examination including, but
45 not limited to, a digital rectal examination and a prostate-specific
46 antigen test for men age 50 and over who are asymptomatic and for
47 men age 40 and over with a family history of prostate cancer or
48 other prostate cancer risk factors. The bill expands the definition of

1 “prostate cancer screening” to mean medically viable methods for
2 the detection and diagnosis of prostate cancer, which includes a
3 digital rectal exam and the prostate-specific antigen test and
4 associated laboratory work. “Prostate cancer screening” shall also
5 include subsequent follow up testing as direct by a physician,
6 including, but not limited to:

- 7 (1) urinary analysis;
- 8 (2) serum biomarkers;
- 9 (3) medical imaging, including, but not limited to, magnetic
10 resonance imaging.

11 The bill also extends the prostate cancer screening requirements
12 to commercial individual health insurers, health benefits plans
13 issued pursuant to the New Jersey Individual Health Coverage and
14 Small Employer Health Benefits Programs, the State Health
15 Benefits Program, and the School Employees’ Health Benefits
16 Program, which are not required to provide this coverage under
17 current law.

Appendix II

Joseph A. Lagana
Chair

Joseph P. Cryan
Vice-Chair

Gordon M. Johnson
Jon M. Bramnick
Robert W. Singer



Liza Ackerman
Jamie Galembo
Office of Legislative Services
Committee Aides
609-847-3845

NEW JERSEY LEGISLATURE

SENATE COMMERCE COMMITTEE

STATE HOUSE ANNEX • P.O. BOX 068 • TRENTON, NJ 08625-
0068
www.njleg.gov

February 5, 2026

New Jersey Mandated Health Benefits Advisory Commission
P.O. Box 325
Trenton, NJ 08625

Dear Members of the Commission:

As the Chair of the Senate Commerce Committee, I respectfully request the Commission to review and prepare a written report of Senate Bill 1796, sponsored by Senator Singleton and Senator Stack. The bill expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

If you have any questions, please do not hesitate to contact Allison Meyers or Sadie Novak, Senate Commerce Committee Aides, at 609-847-3700. Thank you for your immediate attention to this matter.

Sincerely,

Joseph A. Lagana
Senator, 38th District

CC: Allison Meyers
Policy Analyst
Senate Majority Office

Sadie Novak
Policy Analyst
Senate Majority Office